Effect of Neural Constraints on Movement in Stroke
ConditionStroke
Trial statusRecruiting
Trial phaseEarly Phase 1
Trial typeInterventional
Biological sexAll
Age18-80
SponsorNorthwestern University
About this trial
This study investigates the effects of Tizanidine on the voluntary movement controls of the arms of participants who have had a stroke and have not had a stroke by measuring medication-induced changes in upper extremity kinematics, pupillometry, and brain activity. Tizanidine is approved by the U.S. Food and Drug Administration. Understanding how different areas of the brain are involved in movement impairments may help rehabilitation efforts and assist in restoring healthy movement in individuals who have had a stroke.
Eligibility criteria
Qualifiers
History of unilateral supratentorial ischemic stroke that occurred at least six months prior to enrollment
Age between 18-80
Paresis confined to one side, with substantial motor impairment of the upper limb and some residual voluntary movement (Upper Extremity Fugl-Meyer Assessment in the range of 10-50/66, Chedoke McMaster Stroke Assessment Hand section <=4)
Ability to communicate, understand, and provide informed consent
Disqualifiers
Motor or sensory impairment in the non-affected limb (FMA<66, filament >3.6)
Any brainstem and/or cerebellar lesion
untreated cardiovascular disease
History of neurologic disorder other than stroke that affects the arms
Trial design
Treatments tested in this trial
- Tizanidine
- Placebo
Treatment groups
64 Participants
are divided into 2 treatment groupsSponsors and collaborators
Northwestern University
Lead sponsor
Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
Collaborator
Source ClinicalTrials.gov